Results 11 to 20 of about 743,614 (307)

Persistence and Adherence to Cardiovascular Medicines in Australia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background The burden of cardiovascular disease is increasing, with many people treated for multiple cardiovascular conditions. We examined persistence and adherence to medicines for cardiovascular disease treatment or prevention in Australia.
Juliana de Oliveira Costa, Jialing Lin, Sallie‐Anne Pearson, Nicholas A. Buckley, Andrea L. Schaffer, Michael O. Falster   +5 more
doaj   +1 more source

Infectious agents in atherosclerotic cardiovascular diseases through oxidative stress [PDF]

, 2017
Accumulating evidence demonstrates that vascular oxidative stress is a critical feature of atherosclerotic process, potentially triggered by several infectious agents that are considered as risk co-factors for the atherosclerotic cardiovascular diseases (
Di Pietro, M, Falasca, F, Filardo, S, Sessa, R., Turriziani, O   +4 more
core   +5 more sources

Natural AMPK Activators in Cardiovascular Disease Prevention

Frontiers in Pharmacology, 2022
Cardiovascular diseases (CVD), as a life-threatening global disease, is receiving worldwide attention. Seeking novel therapeutic strategies and agents is of utmost importance to curb CVD.
Reza Heidary Moghaddam, Zeinab Samimi, Sedigheh Asgary, Pantea Mohammadi, Soroush Hozeifi, Fatemeh Hoseinzadeh‐Chahkandak, Suowen Xu, Mohammad Hosein Farzaei, Mohammad Hosein Farzaei   +8 more
doaj   +1 more source

Diabetes: how to manage cardiovascular risk in secondary prevention patients

Drugs in Context, 2022
Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure ...
Sarah L Anderson, Joel C Marrs
doaj   +1 more source

Targeting acute hyperglycaemia in clinical practice [PDF]

, 2007
The UKPDS established the benefit of tight glycaemic control in preventing microvascular disease but was unable to demonstrate an effect on cardiovascular disease.
Heller, S.
core   +1 more source

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists

American Journal of Preventive Cardiology, 2023
Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities.
Apurva Khedagi, Cara Hoke, Michelle Kelsey, Andrea Coviello, W. Schuyler Jones, Larry R. Jackson, II, Manesh R Patel, Rob W. McGarrah, Neha J Pagidipati, Nishant P. Shah   +9 more
doaj   +1 more source

Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]

, 2018
Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J., Petrie, John R., Touyz, Rhian M.   +2 more
core   +1 more source

Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes [PDF]

, 2017
Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors may reduce cardiovascular and heart failure risk in patients with type 2 diabetes mellitus (T2DM).
Butler, Javed, Davies, Michael J., Desai, Mehul, Januzzi, James L., Jarolim, Petr, Sattar, Naveed, Vijapurkar, Ujjwala   +6 more
core   +1 more source

The impact of cardiovascular drugs on the efficacy of local anesthesia in dentistry

Biomedical Papers, 2016
Background and Aim. Drugs used chronically by patients with diseases of the cardiovascular system (group C of the ATC classification) may act on adrenergic receptors and/or certain ion channels, which gives them the potential to interact with the action
Мarko J. Milosavljevic, Slobodan M. Jankovic   +1 more
doaj   +1 more source

Production and market comparison of urokinase and streptokinase as effective and cheap fibrinolytic agents for treatment of cardiovascular diseases

Acta Scientiarum: Technology, 2022
 Failure of hemostasis and the formation of blood clots in the arteries are the main reasons that provoke the onset of cardiovascular diseases (CVDs) such as myocardial infarction and ischemic stroke.
Ali Nawaz, Ikram ul Haq, Haseeb Amin, Zinnia Shah, Ammar Javed, Hamid Mukhtar, Fatima Akram   +6 more
doaj   +1 more source